JP2014523913A - 抗がん治療法で用いるためのアデノウイルスe1a断片 - Google Patents

抗がん治療法で用いるためのアデノウイルスe1a断片 Download PDF

Info

Publication number
JP2014523913A
JP2014523913A JP2014521732A JP2014521732A JP2014523913A JP 2014523913 A JP2014523913 A JP 2014523913A JP 2014521732 A JP2014521732 A JP 2014521732A JP 2014521732 A JP2014521732 A JP 2014521732A JP 2014523913 A JP2014523913 A JP 2014523913A
Authority
JP
Japan
Prior art keywords
cell
cells
cancer
vector
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014521732A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014523913A5 (cg-RX-API-DMAC7.html
Inventor
モーリス グリーン
ポール エム. レーベンシュタイン
Original Assignee
セントルイス ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セントルイス ユニバーシティ filed Critical セントルイス ユニバーシティ
Publication of JP2014523913A publication Critical patent/JP2014523913A/ja
Publication of JP2014523913A5 publication Critical patent/JP2014523913A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
JP2014521732A 2011-07-20 2012-07-18 抗がん治療法で用いるためのアデノウイルスe1a断片 Pending JP2014523913A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161509891P 2011-07-20 2011-07-20
US61/509,891 2011-07-20
PCT/US2012/047198 WO2013012922A1 (en) 2011-07-20 2012-07-18 Adenovirus e1a fragments for use in anti-cancer therapies

Publications (2)

Publication Number Publication Date
JP2014523913A true JP2014523913A (ja) 2014-09-18
JP2014523913A5 JP2014523913A5 (cg-RX-API-DMAC7.html) 2015-09-10

Family

ID=47556185

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014521732A Pending JP2014523913A (ja) 2011-07-20 2012-07-18 抗がん治療法で用いるためのアデノウイルスe1a断片

Country Status (4)

Country Link
US (1) US8716014B2 (cg-RX-API-DMAC7.html)
EP (1) EP2734219B1 (cg-RX-API-DMAC7.html)
JP (1) JP2014523913A (cg-RX-API-DMAC7.html)
WO (1) WO2013012922A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017223385A1 (en) * 2016-06-22 2017-12-28 The Children's Hospital Of Philadelphia Protein vii fragments and methods of use thereof for the treatment of inflammatory disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001502538A (ja) * 1996-10-18 2001-02-27 ターゲティッド・ジェネティクス・コーポレイション ミニe1a遺伝子及び遺伝子産物
US7883888B2 (en) * 2000-04-05 2011-02-08 The Research Foundation —The State University of New York Peptides selectively lethal to malignant and transformed mammalian cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2250222A1 (en) 1996-03-20 1997-09-25 Mien-Chie Hung Sensitization of her-2/neu overexpressing cancer cells to chemotherapy
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
KR100972618B1 (ko) 2007-10-19 2010-07-27 국립암센터 허셉틴을 이용한 유방암 진단 키트, 조성물 및 이들을이용하여 허셉틴 민감성 her2 과발현 세포를 검출하는방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001502538A (ja) * 1996-10-18 2001-02-27 ターゲティッド・ジェネティクス・コーポレイション ミニe1a遺伝子及び遺伝子産物
US7883888B2 (en) * 2000-04-05 2011-02-08 The Research Foundation —The State University of New York Peptides selectively lethal to malignant and transformed mammalian cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6016024509; Oncogene Vol.14,No.16, 1997, p1965-1971 *
JPN6016024511; Gene Therapy Vol.5,No.11, 1998, p1538-1544 *
JPN6016024513; Oncogene Vol.14,No.5, 1997, p561-568 *
JPN6016024515; Oncogene Vol.15,No.8, 1997, p953-960 *

Also Published As

Publication number Publication date
EP2734219A1 (en) 2014-05-28
US20130023481A1 (en) 2013-01-24
EP2734219A4 (en) 2015-03-04
EP2734219B1 (en) 2016-11-23
WO2013012922A1 (en) 2013-01-24
US8716014B2 (en) 2014-05-06

Similar Documents

Publication Publication Date Title
JP6072414B2 (ja) 腫瘍選択的e1aおよびe1b変異体
JP4822490B2 (ja) 腫瘍形成形質転換に関連する内因性レトロウイルスポリペプチド
JP4813746B2 (ja) 染色体3p21.3遺伝子は腫瘍サプレッサーである
JPH10503361A (ja) 組換えp53アデノウイルス方法と組成物
US7169384B2 (en) Tumor suppressor CAR-1
US9140705B2 (en) Tumor suppressor killin
WO2001038528A1 (fr) Proteine inhibitrice de la proliferation cellulaire, polynucleotide, polynucleotide antisens de ce polynucleotide, inhibiteurs de proliferation cellulaire, diagnostics de cancers, remedes anticancereux et composition pour therapie genique les utilisant
ES2337696T3 (es) Metodos para aumentar la eficacia de la terapia contra el cancer.
WO2011091716A1 (zh) 表皮生长因子受体变异体
WO2014191608A1 (es) Péptidos derivados de la conexina 43 y composición farmacéutica para el tratamiento del cáncer
US6894157B2 (en) Guanylate binding protein (GBP-1) as inhibitor of cell proliferation and molecular marker for the determination of the stage of cellular differentiation
JP2014523913A (ja) 抗がん治療法で用いるためのアデノウイルスe1a断片
JP2001514015A (ja) Ts10q23.3と称する腫瘍抑制因子
US10618944B2 (en) Tumor suppressor SALL1 as a therapeutic agent for treating cancer
WO2012048667A1 (zh) 表皮生长因子受体的外显子缺失变异体
JP2003501362A (ja) 脈管形成インヒビターとしてのc−cam
JP2023529319A (ja) 腫瘍ターゲティングの向上及びウイルスの大量産生が可能な間葉系幹細胞
US20090263396A1 (en) Inhibitors of t-darpp for use in combination anti-cancer therapies
JP2001512325A (ja) 改変型レチノブラストーマ腫瘍抑制タンパク質
US8187586B2 (en) Methods of inducing apoptosis in hyperproliferative cells
RU2846551C1 (ru) Мезенхимальные стволовые клетки, которые обеспечивают улучшение нацелевания на опухоль и массовое получение вирусов
Jandick et al. CREATION AND CHARACTERIZATION OF A RECOMBINANT MAMMALIAN ORTHOREOVIRUS EXPRESSING HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 PEPTIDES
EP3738972A1 (en) Parvolysine
Peerlinck Development of a WNT-selective oncolytic adenovirus for imaging the therapy of colorectal cancers.

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150717

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170301